Shots:
- Amgen & AZ have reported the P-III (DeLLphi-305) trial data assessing Imfinzi + Imdelltra vs Imfinzi as the 1L maintenance treatment for pts (n=563) with ES-SCLC who have not progressed following induction treatment with Imfinzi + PT-based CT & etoposide
- Trial showed improved OS (1EP) & demonstrated benefits across 2EPs, incl. PFS & ORR; data to be presented at an upcoming meeting & shared with global regulatory authorities
- Imfinzi is a PD-L1-targeting monoclonal antibody that blocks PD-L1 interactions with PD-1 & CD80, while Imdelltra activates T cells by simultaneously targeting DLL3 on tumor cells & CD3 on T cells to kill DLL3-expressing SCLC cells
Ref: Businesswire | Image: AstraZeneca & Amgen | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
